Grimes & Company Inc. Purchases 297 Shares of AstraZeneca PLC (NASDAQ:AZN)

Grimes & Company Inc. raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,393 shares of the company’s stock after purchasing an additional 297 shares during the quarter. Grimes & Company Inc.’s holdings in AstraZeneca were worth $353,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in AZN. FMR LLC lifted its stake in shares of AstraZeneca by 1.1% during the 3rd quarter. FMR LLC now owns 23,117,447 shares of the company’s stock worth $1,801,080,000 after purchasing an additional 258,477 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after buying an additional 1,522,715 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of AstraZeneca by 5.3% in the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after buying an additional 524,175 shares in the last quarter. Clearbridge Investments LLC grew its position in shares of AstraZeneca by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after buying an additional 186,010 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in shares of AstraZeneca by 109.6% during the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after acquiring an additional 1,605,758 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Up 0.7 %

AZN stock opened at $69.06 on Monday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The firm has a market cap of $214.16 billion, a PE ratio of 33.04, a PEG ratio of 1.13 and a beta of 0.46. The firm’s 50 day moving average price is $66.44 and its 200-day moving average price is $74.17. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.87 earnings per share. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.12 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.